Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid antidepressant combined with sleep regulation for depression with insomnia
ChiCTR2300070756Phase 4Completed
- Sponsor
- Affiliated Hospital of Shandong Second Medical University
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ketamine in major depressive disorder (MDD) and Insomnia, sponsored by Affiliated Hospital of Shandong Second Medical University. Primary endpoints: Hamilton Depression Scale (HAMD) at 3 months and Functional MRI (fMRI) at 3 days. Started Apr 2023; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on ChiCTR2300070756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070756.